• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

June 4, 2021

Apalutamide Demonstrates Survival Benefit, Maintenance of Health-Related Quality of Life for Certain Patients With Prostate Cancer

Author(s):

Kristen Coppock, MA, Managing Editor
Conference|ASCO Annual Meeting - American Society of Clinical Oncology Annual Meeting

Results from the phase 3 TITAN study shows a combination therapy that includes apalutamide may achieve survival benefit without significant burden of adverse effects.

Data from a recent phase 3 study has demonstrated a survival benefit of apalutamide (Erleada; Janssen Pharmaceutical Companies) plus androgen deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC).1 Final analysis of data from the TITAN study (NCT02489318) also showed a survival benefit from the combination therapy without significant patient-reported adverse effects, compared to placebo plus ADT, as well as maintenance of health-related quality of life (HRQoL).2

Apalutamide is an oral androgen receptor inhibitor that is FDA-approved for the treatment of patients with mCSPC and for patients with non-metastatic castration-resistant prostate cancer (nmCRPC).2 Scheduled to be presented during the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, the latest results of the TITAN study are consistent with previous data for adverse effects with only ADT.1,2

"Concern about [adverse] effects and their resulting burden on quality of life can be a barrier for patients when considering treatment options," said Neeraj Agarwal, MD, of the University of Utah Huntsman Cancer Institute in Salt Lake City, and the lead investigator for the TITAN study, in a prepared statement. "The significant long-term overall survival benefit we've seen demonstrated with [apalutamide], with no impact on quality of life as reported by patients, underscores the important role of this therapy in the treatment of advanced prostate cancer."

According to Janssen, the TITAN study included 1052 patients with mCSPC in 23 countries across 260 sites. Patients were randomized equally to groups receiving apalutamide or placebo, with both groups also receiving ADT.1,2 No significant differences in quality of life were observed between patients who received apalutamide plus ADT, and patients who received placebo plus ADT.2

Patients in both groups were assessed using the Brief Pain Inventory (BPI)-Short Form and Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaires. Those assessments revealed that patients reported they were relatively asymptomatic with a good baseline HRQoL.2

On the BPI pain severity scale of 0 (no pain) to 10 (worst pain), median patient scores were 1.1 in the apalutamide group and 1 in the placebo plus ADT group. On the FACT-P HRQoL scale (1-156, higher score = better quality of life), median patient scores were 113 in the apalutamide group and 113.3 in the placebo plus ADT group.2

Apalutamide plus ADT was also shown to help maintain physical, social and family, emotional, functional, and mental well-being beyond 2 years, as assessed by FACT-P. According to Janssen, there were no significant differences between groups in median time to deterioration in any BPI or FACT-P scores, further demonstrating maintenance of quality of life with apalutamide.2

"Patient-reported outcomes provide meaningful input into treatment decisions by giving us insights into the way patients feel and function," said Mary Guckert, RN, MSN, vice president, development leader, prostate cancer, Janssen Research & Development, LLC, in a prepared statement.



REFERENCES

  1. Agarwal N, Chowhury S, Bjartell A, et al. Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). J Clin Oncol 39, 2021 (suppl 15; abstr 5068). DOI: 10.1200/JCO.2021.39.15_suppl.5068
  2. Long-term Erleada (apalutamide) patient-reported outcomes data in metastatic castration-sensitive prostate cancer demonstrate maintenance of health-related quality of life for patients [news release]. May 26, 2021; Janssen. Accessed June 3, 2021. https://www.janssen.com/long-term-erleada-apalutamide-patient-reported-outcomes-data-metastatic-castration-sensitive

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Austin Texas | Image credit: Kevin Ruck - stock.adobe.com
Pharmacy Times OPC
Related Content
Advertisement
HRT Hormone Therapy sign surrounded by plants and hormone therapy pills | Image Credit: © tilialucida - stock.adobe.com
July 2nd 2025

Study Links Specific Hormone Therapies to Breast Cancer Risk in Younger Women

Alexandra Gerlach, Associate Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
Microscopic view of bone marrow slide feature are suggestive Multiple myeloma, also known as myeloma, is a type of bone marrow cancer.
Published: July 2nd 2025 | Updated: July 2nd 2025

FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma

Luke Halpern, Assistant Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Group of women holding breast cancer ribbon | Image Credit: © Rawpixel.com - stock.adobe.com
July 1st 2025

Study Reveals Alarming Gaps in HER2 Therapy Access for Patients With Breast Cancer

Alexandra Gerlach, Associate Editor
digital representation of car t cells targeting lymphoma cells vibrant and scientific lymphoma car t cell therapy for lymphoma
June 30th 2025

FDA Removes REMS for Currently Approved BCMA-, CD19-Directed CAR T Cell Immunotherapies

Luke Halpern, Assistant Editor
Related Content
Advertisement
HRT Hormone Therapy sign surrounded by plants and hormone therapy pills | Image Credit: © tilialucida - stock.adobe.com
July 2nd 2025

Study Links Specific Hormone Therapies to Breast Cancer Risk in Younger Women

Alexandra Gerlach, Associate Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
Microscopic view of bone marrow slide feature are suggestive Multiple myeloma, also known as myeloma, is a type of bone marrow cancer.
Published: July 2nd 2025 | Updated: July 2nd 2025

FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma

Luke Halpern, Assistant Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Group of women holding breast cancer ribbon | Image Credit: © Rawpixel.com - stock.adobe.com
July 1st 2025

Study Reveals Alarming Gaps in HER2 Therapy Access for Patients With Breast Cancer

Alexandra Gerlach, Associate Editor
digital representation of car t cells targeting lymphoma cells vibrant and scientific lymphoma car t cell therapy for lymphoma
June 30th 2025

FDA Removes REMS for Currently Approved BCMA-, CD19-Directed CAR T Cell Immunotherapies

Luke Halpern, Assistant Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.